Trius reports tedizolid data in ABSSSI

Trius Therapeutics Inc. (NASDAQ:TSRX) said once-daily oral tedizolid met the primary endpoint of non-inferiority to twice-daily oral linezolid in the proportion of patients who achieved a clinical res...